NEUTRON ENTERPRISES INC.(NASDAQBB:NTRN) announces accepted appointment of Dr. Uri Sagman to its advisory committee.
April 14 2004 - 11:16AM
PR Newswire (US)
NEUTRON ENTERPRISES INC.(NASDAQBB:NTRN) announces accepted
appointment of Dr. Uri Sagman to its advisory committee. TORONTO,
April 14 /PRNewswire-FirstCall/ -- NTRN recently launched its
wholly owned subsidiary Nanosphere Technologies Inc. to bring
together world class technology experts to assist, incubate and
accelerate emerging technologies with global commercialization
potential. Dr. Sagman will be providing strategic counsel on
numerous technology in licensing, acquisition and investment
opportunities. Dr. Sagman is the co-founder and Executive Director
of the Canadian Nano Business Alliance, an association dedicated to
the promotion of the nanotechnology sector in Canada. The Canadian
Nano Business Alliance has a diverse membership, which includes
representation of government agencies, academic centers of
excellence, industry and the investment community. Dr. Sagman is
cofounder and President of C Sixty Inc, (http://www.csixty.com/).
At C Sixty, Dr. Sagman recruited some of the world's leading
scientists, including the 1996 Nobel Prize awardee and
co-discoverer of fullerenes, to advance the development of
fullerene-based technology for biomedical applications. To that
end, Dr. Sagman has enlisted a comprehensive R&D network, based
at leading academic centers, which include Rice University, UCLA,
Columbia University, Dartmouth University, the University of
Toronto, Erlangen University in Germany, and the University of
Taiwan. Dr. Sagman is the Chairman of GRN Health International
Inc., a globally based academic research organization dedicated to
medical research and development. Dr. Sagman is currently engaged
in the development of strategies for National Nanotechnology
Initiative programs in several countries, specializing in the
development of paradigms for public and private sector alliances.
In addition, Dr. Sagman's efforts are focused on the application of
nanotechnology for problems of global scope. Dr. Sagman is a
medical oncologist, a fellow of the Royal College of Physicians and
Surgeons of Canada, and a fellowship recipient of the Medical
Research Council of Canada. He is a recognized researcher in the
field of clinical oncology, tumor biology and immunology. Dr.
Sagman obtained his training at McGill University, The University
of Calgary, The University of Toronto and Oxford University. Dr.
Sagman is the recipient of numerous awards and citations including
the Young Investigator awards of the American Society of Clinical
Oncology (ASCO) and the American Association for Cancer Research
(AACR). He has organized and participated as keynote speaker at
numerous nanotechnology-based conferences. Dr. Sagman has been
extensively profiled in numerous journal and press publications,
including Time Magazine, Newsweek, the Economist, the New York
Times, Red Herring, Technology Review, Chemical Engineering, the
National Post, the Houston Chronicle, and The Toronto Star amongst
others. About Neutron Enterprises Inc.: Neutron Enterprises Inc. is
a publicly traded venture capital and private equity buyout firm
that seeks to continuously acquire technology and businesses
through three distinct divisions. University Medical Enterprises
Inc. accelerates emerging medical applications and therapeutic
molecules in the areas of oncology and cardiology. Nanosphere
Technologies Inc. invests in nano technologies and materials
companies in the life sciences, fibre optic, semiconductor, energy,
chemical and defense industries. Life Sciences Private Equity Inc.
seeks to invest in and acquire established product and service
health care businesses generating positive free cash flow from
operations. This press release does not constitute an offer to sell
or a recommendation to purchase any securities. This press release
may contain forward-looking statements, including the company's
beliefs about its business prospects and future results of
operations. These statements involve risks and uncertainties. Among
the important additional factors that could cause actual results to
differ materially from those forward-looking statements are risks
associated with the overall economic environment, the successful
execution of the company's plan of operation, changes in the
company's anticipated earnings, continuation of current contracts,
changes in drug approval and other applicable regulations, and
other factors detailed in the company's filings with the Securities
and Exchange Commission, including its most recent Form 10-QSB
Quarterly Reports. In addition, the factors underlying company
forecasts are dynamic and subject to change and therefore those
forecasts speak only as of the date they are given. The company
does not undertake to update them; however, it may choose from time
to time to update them and if it should do so, it will disseminate
the updates to the investing public. DATASOURCE: Neutron
Enterprises, Inc. CONTACT: Russell J. Hoffman, (914) 924-0365
Copyright